Related Experiment Video
Updated: Aug 25, 2026

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Minimizing the immunogenicity of protein therapeutics
Arthur J Chirino1, Marie L Ary, Shannon A Marshall
1Xencor 111 W. Lemon Avenue, Monrovia, CA 91016, USA. art@xencor.com
Abstract:
As is cautioned in many package inserts, 'with all therapeutic proteins, there is a potential for immunogenicity'. Immunogenicity problems in humans, which currently can be detected only in clinical trials or after product launch, pose a significant barrier to the development and acceptance of protein drugs. Recent and ongoing research, presented in this review, seeks to address the challenge of protein therapeutic immunogenicity by elucidating the mechanisms underlying immune recognition of protein therapeutics, establishing preclinical methods for assessing immunogenicity and developing strategies for minimizing immune responses.
Related Concept Videos
Immunoprecipitation
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Inhibitors of Viral Protein Synthesis
Production of Pharmaceuticals
Microorganisms in Medicine and Therapeutics
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.

